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Abstract. 
 
In a recently developed human breast cancer 
model, treatment of tumor cells in a 3-dimensional cul-
ture with inhibitory 
 
b
 
1-integrin antibody or its Fab 
fragments led to a striking morphological and func-
tional reversion to a normal phenotype. A stimulatory 
 
b
 
1-integrin antibody proved to be ineffective. The 
newly formed reverted acini re-assembled a basement 
membrane and re-established E-cadherin–catenin com-
plexes, and re-organized their cytoskeletons. At the 
same time they downregulated cyclin D1, upregulated 
p21
 
cip,waf-1
 
, and stopped growing. Tumor cells treated 
with the same antibody and injected into nude mice had 
significantly reduced number and size of tumors in 
nude mice. The tissue distribution of other integrins 
was also normalized, suggesting the existence of inti-
mate interactions between the different integrin path-
ways as well as adherens junctions. On the other hand, 
nonmalignant cells when treated with either 
 
a
 
6 or 
 
b
 
4 
function altering antibodies continued to grow, and had 
disorganized colony morphologies resembling the un-
treated tumor colonies. This shows a significant role of 
the 
 
a
 
6/
 
b
 
4 heterodimer in directing polarity and tissue 
structure. The observed phenotypes were reversible 
when the cells were disassociated and the antibodies re-
moved. Our results illustrate that the extracellular ma-
trix and its receptors dictate the phenotype of mam-
mary epithelial cells, and thus in this model system the 
tissue phenotype is dominant over the cellular geno-
type.
 
T
 
he
 
 extracellular matrix (ECM)
 
1
 
 modulates breast
tissue homeostasis in vivo, and has been shown to
regulate growth, differentiation, and apoptosis of
normal murine and human mammary epithelial cells (MEC)
in culture (Barcellos-Hoff et al., 1989; Petersen et al., 1992;
Strange et al., 1992; Boudreau et al., 1995
 
b
 
; for review see
Damsky and Werb, 1992; Adams and Watt, 1993; Roskel-
ley et al., 1995). Moreover, perturbations in cell-ECM in-
teractions are a consistent feature of mammary tumors
and cells in vivo and in culture (Petersen et al., 1992; Bern-
field et al., 1993; Zutter et al., 1993; Sympson et al., 1994;
Bergstraesser and Weitzman, 1994; Howlett et al., 1995).
The mechanism by which ECM-mediated signal transduc-
tion events can lead to diverse changes in gene expression
is now being unraveled. For example, it has been shown
that the ECM mediates both biochemical and biomechani-
cal signaling events (Roskelley et al., 1994), and that cell
shape in turn can profoundly influence the phenotypic re-
sponse of cells to the ECM (Dhawan and Farmer, 1994; Ing-
ber et al., 1995). However, how alterations in these path-
ways can lead to mammary tumors is at present unknown.
Because tumor cells have an altered response to the ECM
and their microenvironment, we have argued that ECM-
signaling pathways contain tumor suppressor checkpoints
which impinge upon, and direct, cell and tissue architec-
ture (Petersen et al., 1992; Howlett et al., 1994, 1995). If
this were so, then the context and integration of adhesion-
derived signaling networks could dictate the final tissue
phenotype (Bissell et al., 1982). 
Epithelial tissue architecture and function are orches-
trated and maintained through multimeric adhesion com-
plexes known to interact directly with elements of the ac-
tin and intermediate filament cytoskeleton, as well as with
kinases and phosphatases (Schmidt et al., 1993; Hodivala
and Watt, 1994; for review see Gumbiner 1996; Drubin and
Nelson, 1996; Giancotti and Mainiero, 1994; Dedhar, 1995;
Ashkenas et al., 1996). The mechanism whereby these ad-
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hesive interactions control the spatio-temporal fate of cells,
and direct higher order tissue structure is poorly under-
stood, although a dynamic competition between integrins
and cadherins for polymerized actin microfilaments, and a
modulation of this interaction by tyrosine kinases appears
likely (Adams and Watt, 1993; Drubin and Nelson, 1996).
Thus, the coordinated regulation of integrins and adherens
junctions has been described during keratinocyte differen-
tiation (Hodivala and Watt, 1994; Braga et al., 1995; Hotchin
et al., 1995), while cell–cell adhesion may be modulated by
molecules such as fascin, an actin bundling/motility-associ-
ated protein (Tao et al., 1996). Furthermore, the impor-
tance of 
 
b
 
1-integrins in directing cell–cell and cell-ECM
polarity and differentiation has been shown by studies in
kidney cells (Ojakian and Schwimmer, 1994; Schoenen-
berger et al., 1994) and keratinocytes (Symington et al.,
1993; Watt et al., 1993). Also, the redistribution of 
 
a
 
6/
 
b
 
4-
integrins has been reported to be associated with the es-
tablishment of epithelial cell polarity (Giancotti, 1996;
Borradori and Sonnenberg, 1996), and integrin knockout
studies have documented profound tissue degeneration
and disorganization in 
 
b
 
4-integrin null mice (Dowling et
al., 1996). Thus, there is evidence which suggests that inte-
grin and adherens receptor pathways direct the organiza-
tion of epithelial tissue structure. However, how these
events are coordinated, and whether there is a direct reci-
procity or hierarchy in these interactions is not known. 
A common feature of mammary epithelial tumors in
vivo is a disruption of tissue organization and polarity. Con-
sistent with their structural function, catenin-cadherin–
cytoskeletal interactions have been shown to be frequently
altered in breast cancers, and loss of cell–cell interactions
is associated with altered tissue organization and increased
tumor invasiveness (for review see Takeichi, 1993; Som-
mers, 1996; Alford and Taylor-Papadimitriou, 1996). Al-
though cadherins and catenins are often downregulated or
absent in invasive breast cancers, there are many examples
of mammary carcinoma in situ and aggressive, metastatic
breast tumors in vivo that express the full complement of
adherens proteins. Instead the cells in these tissues have
lost their ability to assemble adherens junctions (Birchmeier
and Behrens, 1993; Moll et al., 1994; Sommers, 1996).
While the precise cause(s) of this perturbation have yet to
be determined, it has been shown that the assembly of ad-
herens junctions can be disrupted by growth factors and
oncogenes, and also modified by kinases and phosphatases
(Warren and Nelson, 1987; D’Souza and Taylor-Papadimi-
triou, 1994; Hoschuetzky et al., 1994; Ochiai et al., 1994;
Kinch et al., 1995). This suggests that connections exist be-
tween adherens junctions and signal transduction path-
ways and implies the potential for structural plasticity.
The disrupted tissue architecture observed in mammary
adenocarcinoma is also frequently associated with alter-
ations in integrin heterodimer profiles (D’Ardenne et al.,
1991; Natali et al., 1992; Zutter et al., 1993; Gui et al., 1995;
Howlett et al., 1995). Changes in 
 
b
 
1-, 
 
b
 
4-, 
 
a
 
2-, 
 
a
 
3, and 
 
a
 
6-
integrins have been reported for mammary tumor cell
lines and in tissue sections, and were shown to be associ-
ated with tissue disorganization, loss of polarity, increased
tumor aggressiveness, and metastasis (Natali et al., 1992;
Berdichevsky et al., 1994; Rossen et al., 1994; Gui et al.,
1995; Zutter et al., 1995). A relationship between altered
signal transduction via integrins and the adherens junction
pathways, and its relevance to the origin of the tumor phe-
notype has not been directly examined. This is mainly due
to the lack of appropriate model systems in which such
changes can be studied (Weaver et al., 1995).
We have thus taken advantage of a unique epithelial cell
model of breast cancer developed by Briand and cowork-
ers (Briand et al., 1987, 1996). The HMT-3522 breast can-
cer series was established under chemically defined condi-
tions from a breast biopsy of a woman with a nonmalignant
breast lesion (Briand et al., 1987; Nielsen and Briand,
1989). A subline of these cells, generated from passage
118, became spontaneously tumorigenic after an addi-
tional 120 passages (passage 238), while the parental line
remained nontumorigenic for greater than 400 passages
(Nielsen et al., 1994; Briand et al., 1996). In this study we
used nonmalignant S-1 cells at passage 50 (“normal”; S-1)
and the tumorigenic progeny at passage 238 (T4-2; re-
ferred to as mt-1 in Briand et al., 1996). The latter cells were
shown to have a trisomy of chromosome 7p in addition to
other genetic alterations such as a p53 mutation and a c-
 
myc
 
amplification (Madsen et al., 1992; Moyret et al., 1994;
Nielsen et al., 1994; Briand et al., 1996). These two cell lines,
one originating from the other by spontaneous genetic
events, therefore, provide a unique tool for addressing the
specific mechanisms involved in malignant conversion in
the breast. In this paper, we postulated that if there were a
cause and effect relationship between perturbed tissue or-
ganization, loss of cell–cell interactions and altered ECM-
signaling through integrins on the one hand, and tumor
formation on the other hand, it should be possible to mod-
ify morphology and behavior of these malignant cells by
altering cell-ECM interactions.
Here we show that modification of cell surface 
 
b
 
1- and
 
b
 
4-integrins in a 3-dimensional (3-D) basement mem-
brane (BM) assay (Petersen et al., 1992), influences mam-
mary tissue morphogenesis and also regulates cell growth
and signal transduction. Furthermore, cellular integrins,
when normalized, promote the assembly of adherens junc-
tions and influence the cytostructure of these cells, thereby
implying that these two adhesion systems may be intercon-
nected. Finally, our results suggest that growth as well as
malignant behavior is regulated at the level of the tissue
(acini) organization, i.e., the tissue structure appears to de-
termine the phenotype which in turn overrides the cellular
genotype.
 
Materials and Methods
 
Substrates and Antibodies
 
Commercially prepared EHS matrix (Matrigel, Collaborative Research,
Waltham, MA) was used for reconstituted basement membrane assays,
and Vitrogen (rat tail collagen 1), 
 
z
 
3 mg/ml (Vitrogen 100, Celtrix Labo-
ratories), was used for thinly coating the surfaces of culture dishes. Anti-
bodies used for biochemical analysis and immunostaining studies were as
follows: for immunostaining, immunoblotting, and immunoprecipitation
of E-cadherin, 
 
a
 
-catenin, and 
 
b
 
-catenin, we used clones 36, 29, and 14, re-
spectively (Transduction Laboratories, Lexington, NY); for immunostain-
ing of type IV collagen we used clone PHM-12 (Biogenex, San Ramon,
CA); for immunostaining of 
 
b
 
1- and 
 
a
 
6-integrins we used clones AIIB2
and J1B5 (C. Damsky); for immunostaining of 
 
a
 
3-integrin we used clone
P1B5; for immunostaining and immunoprecipitation of 
 
b
 
4-integrin we
used clone 3E1; for immunoblot analysis of 
 
b
 
1-integrin we used clone 
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DF5; for immunoblot analysis of 
 
b
 
4-integrin we used polyclonal rabbit se-
rum; for immunoprecipitation of 
 
b
 
1-integrin we used polyclonal rabbit se-
rum (all from Chemicon International, Temecula, CA); for immunostain-
ing of Ki-67 we used clone MIB; for immunoblot analysis of cyclin D-1 we
used clone 17A6-4; and for immunoblot analysis of p21
 
cip,waf-1
 
 we used
clone EA10 (all from Oncogene Science, Uniondale, NY). Fluorescence
and alkaline phosphatase–conjugated, unlabeled, and nonspecific rat and
mouse IgG’s were from Jackson Laboratories (West Grove, PA) and
HRP-conjugated secondaries were from DAKO (Carpinteria, CA). Anti-
bodies used for integrin function-altering studies within the 3-D reconsti-
tuted basement membrane assay were as follows: for 
 
b
 
1-integrin function-
inhibition we used clone AIIB2 (C. Damsky) and clone JB1a (Chemicon
International); for 
 
b
 
1-integrin function-stimulating we used clone TS2/16
(a kind gift of M. Hemler); for 
 
b
 
4-integrin function-altering we used clone
3E1 (Chemicon International); and for 
 
a
 
6-integrin function-blocking we
used clone GoH3 (Chemicon International).
 
Cell Culture
 
The HMT-3522 mammary epithelial cells (Briand et al., 1987, 1996) were
grown in H14 medium (for further description see Blaschke et al., 1994)
consisting of DMEM:F12 medium (GIBCO BRL, St. Louis, MO), con-
taining 250 ng/ml insulin (Boehringer Mannheim, Indianapolis, IN), 10 
 
m
 
g/ml
transferrin (Sigma, St. Louis, MO), 2.6 ng/ml sodium selenite (Collabora-
tive Research), 10
 
2
 
10
 
 M estradiol (Sigma), 1.4 
 
3 
 
10
 
2
 
6
 
 M hydrocortisone
(Collaborative Research), and 5 
 
m
 
g/ml prolactin (Sigma). The S-1 cells
were propagated as monolayers on plastic in the presence of 10 ng/ml epi-
dermal growth factor (EGF; Collaborative Research); the T4-2 cells were
grown as monolayers on dishes coated with collagen type I in the absence of
EGF. Three dimensional (3D) cultures were prepared by growing S-1 and
T4-2 cells to confluence as monolayers, followed by trypsinization and em-
bedment into EHS matrices as single cells (8.5 
 
3 
 
10
 
5
 
 cells/ml). Cultures
were routinely grown for 10–12 d in serum-free medium as described above.
 
Indirect Immunofluorescence
and Immunocytochemistry
 
EHS cultures were fixed in either 2% paraformaldehyde at ambient tem-
perature for 20 min or in 1:1 methanol-acetone at 
 
2
 
20
 
8
 
C for 2–3 min.
Specimens were embedded in sucrose, frozen in Tissue-Tek OCT com-
pound (Miles Laboratories, Elkhart, IN), and 5 
 
m 
 
frozen sections were pre-
pared for immunostaining as described previously (Streuli et al., 1991).
Sections were incubated with primary antibodies for 60 min followed di-
rectly by either FITC or Texas red–conjugated secondaries (45 min), or by
biotinylated secondary antibodies (45 min), and either Texas red–conju-
gated streptavidin or HRP-conjugated streptavidin (30 min). Nuclei were
counterstained with di-amino-phenyl-indole (DAPI, Sigma) or hematoxy-
lin (5 min). Control sections were stained with second antibodies only.
 
Morphogenesis Criteria
 
Quantitative analysis of tumor cell conversion efficiency by 
 
b
 
1-integrin func-
tion blocking antibodies was determined by calculating the percentage of
colonies converted to a “nontumorigenic morphology.” Percent conver-
sion was determined by directly examining the morphology, uniformity,
and size of 2,000–4,000 colonies of S-1, T4-2, and 
 
b
 
1-inhibitory antibody-
treated T4-2 cells (T4-
 
b
 
1). Morphology was assessed in situ by examining
the degree of colony organization visually by phase contrast microscopy,
and by measuring colony diameter using an eyepiece equipped with a mi-
crometer spindle. Colonies were deemed disorganized if they were both
irregular in shape and the colony length exceeded the width by greater
than twofold. Colony organization was also suggested by a lateral and ra-
dially distributed cytoarchitecture, which was visualized by immunostain-
ing for the distribution of actin microfilaments and cytokeratin 18 inter-
mediate filaments, and related to the distribution observed in acini formed
by normal mammary epithelial cells. Polarity was indicated by the pres-
ence of a basally organized BM as determined by collagen IV and laminin
immunostaining, and by basally immunolocalized 
 
a
 
6-, 
 
b
 
4-, and
 
 b
 
1-integrins.
Morphogenic reversion was scored positive by the deduced presence of
adherens junctions as determined by colocalization of E cadherin and 
 
a
 
- and
 
b
 
-catenins at cell–cell contacts.
 
Analysis of Cellular Growth and Apoptosis
 
The proliferative rate of cells in 3-D EHS was assessed by measuring the
thymidine incorporation index. Cryosections (5 
 
m
 
) of 3D cultures were
pulse-labeled for 24 h with [
 
3
 
H]TdR (20 Ci/mmol, New England Nuclear
Research Products, Dupont, Wilmington, DE), air dried, coated with Ko-
dak NTB2 emulsion, developed, and scored visually (100–400 cells) for ra-
diolabelled nuclei. Indices were calculated by expressing this value as a
percentage of the total number of cells scored (Petersen et al., 1992). Cell
growth was determined in monolayers or in 5 
 
m
 
 cryosections after a 12-h
incubation with 10 
 
m
 
M BrdUrd followed by fixation in 70% ethanol, and
staining with anti-BrdUrd using a kit (Boehringer Mannheim), and indices
were calculated as above. Proliferative potential of 100–400 cells was as-
sayed by immunostaining and calculating the Ki-67 labeling index in 5 
 
m
 
cryosections of 3D EHS cultures. Proliferative status was determined also
by counting and immunostaining the number of cells per colony as well as
the average colony size. The colony size was measured directly in 3-D cul-
tures by phase contrast microscopy using an eyepiece equipped with a mi-
crometer spindle, which had been previously calibrated with a ruler. Cell
number per colony was determined by counting the number of DAPI
stained nuclei per colony in cryosections of cells in 3-D. Cell cycle status
was determined by immunoblotting equal amounts of total cell protein ly-
sates for cyclin D1 and p21
 
cip,waf-1
 
 protein levels after separating the pro-
teins by reducing Laemmli gels. Apoptosis was assessed by detection of
FITC-labeled 3'OH DNA ends using an in situ apoptosis kit (Boehringer
Mannheim) in 5 
 
m
 
 cryosections (Boudreau et al., 1996). Cells were scored
(150–200 cells) for the presence of DNA nicks and positively scored cells
for each condition were expressed as a percentage of the total number of
cells scored (apoptotic index).
 
Determination of 
 
a
 
- and 
 
b
 
-Catenin-E-Cadherin 
Adherens Junction Assembly
 
For the determination of total E-cadherin, 
 
a
 
-catenin, and 
 
b
 
-catenin levels,
RIPA lysates (1% NP-40, 0.5% deoxycholate, 0.2% SDS, 150 mM sodium
chloride, 50 mM Tris-HCl, pH 7.4 containing 20 mM sodium fluoride, and
1 mM sodium orthovanadate, 10 
 
m
 
g/ml leupeptin, 10 
 
m
 
g/ml pepstatin, 1
mM Pefabloc [Boehringer Mannheim], 10 
 
m
 
g/ml E64, 25 
 
m
 
g/ml aprotinin,
and 0.5 mM benzamidine) were prepared from cells isolated from EHS by
PBS/EDTA, separated on reducing Laemmli gels and immunoblotted.
For the assessment of the soluble and cytoskeletal-associated E-cadherins,
 
a
 
-catenins and 
 
b
 
-catenins, S-1, and T4-2 colonies were grown for 12 d in 3-D-
reconstituted basement membranes and colonies were isolated using ice-
cold PBS/EDTA (0.01 M sodium phosphate, 138 mM sodium chloride, 5
mM EDTA), homogenized and fractionated into Triton X-100 soluble
and insoluble lysates essentially as described by Nathke et al. (1994). Ly-
sates were separated on Laemmli reducing gels and immunoblotted for
adherens junction proteins. Densitometric analysis of scanned enhanced
chemiluminescence (ECL) film was used for the estimation and calculation of
relative protein levels. For the assessment of the 
 
b
 
-catenin-(or 
 
a
 
-catenin)-
E-cadherin interaction index, S-1, T4-2, and T4-
 
b
 
1 integrin-reverted cells
were grown for 12 d in 3-D EHS. RIPA lysates of equal numbers of cells
in EHS were prepared by directly homogenizing in RIPA, and were im-
munoprecipitated with anti–E-cadherin antibodies. Immunoprecipitants
were separated on reducing Laemmli gels and immunoblotted for E-cadherin,
 
a
 
-catenin, and 
 
b
 
-catenin proteins. ECL films were scanned and subjected
to densitometric analysis for assessment of the relative protein levels. In-
teraction index values were calculated by dividing the densitometric value
determined from the catenin protein coprecipitated with E-cadherin by the
value calculated for the level of E-cadherin protein immunoprecipitated.
For the assessment of in situ cytoskeletal-associated and soluble adherens
junctions proteins, day 12 cultures of S-1 and T4-2 colonies were frozen
(see above) without prior fixation, and fresh 8 
 
m 
 
cryosections were ex-
tracted with fresh CSK buffer (50 mM sodium chloride, 300 mM sucrose,
10 mM Pipes, pH 6.8, 3 mM MgCl
 
2
 
, 0.5% Triton X-100, containing a cock-
tail of protein inhibitors as described above). Sections were extracted for
40 min, fixed in 2% paraformaldehyde for 20 min and immunostained for
E-cadherin, 
 
a
 
-catenin, and 
 
b
 
-catenin proteins. 
 
Determination of Total Levels and Cell Surface
Integrin Expression
 
For the assessment of total 
 
b
 
1- and 
 
b
 
4-integrin levels, cells were grown in
3D EHS cultures for 10–12 d, and colonies were isolated using ice-cold
PBS/EDTA. Colonies were lysed in RIPA and equal amounts of lysate
proteins were separated on reducing Laemmli gels and immunoblotted.
ECL films were scanned and subjected to densitometric analysis for as-
sessment of the relative protein levels. For the determination of colony 
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surface 
 
b
 
1- and 
 
b
 
4-integrins, cells were grown in 3-D EHS cultures for 10–
12 d and colonies were then released from the matrix by 60–90 min incu-
bation at 37
 
8
 
C with dispase (5,000 U/ml caseinolytic activity, Collaborative
Research), washed three times in fresh DMEM:F12 medium and once in
ice-cold PBS. Released colonies were incubated and rocked at 4
 
8
 
C for 60
min with 1 mg/ml sulfo-NHS-biotin (Pierce, Rockford, IL) in PBS to label
the cell surface proteins, washed twice in ice-cold PBS containing 50 mM
glycine, and incubated for 10–15 min on ice in PBS/glycine to stop the re-
action. Colonies were washed three more times in ice-cold PBS/glycine
and lysed in 1% NP-40 lysis buffer also containing 120 mM sodium chlo-
ride, 50 mM Tris-HCl and 10 
 
m
 
g/ml leupeptin, 10 
 
m
 
g/ml pepstatin, 1 mM
Pefabloc (Boehringer Mannheim), 10 
 
m
 
g/ml E64, 25 
 
m
 
g/ml aprotinin, and
0.5 mM benzamidine. Equal numbers of cells (determined by counting the
cells in parallel cultures) or equivalent amounts of extracted proteins,
were immunoprecipitated with anti–
 
b
 
1- or 
 
b
 
4-integrin monoclonal anti-
bodies, separated on nonreducing Laemmli gels, and immunoblotted for
the presence of biotinylated proteins using HRP-conjugated streptavidin
antibody and ECL detection. Irrelevant mouse or rat IgG’s served as non-
specific controls. Exposed films were scanned and subjected to densito-
metric analysis for the determination of intensity differences and relative
quantification. 
 
Preparation of Fab Fragments
 
Rat monoclonal AIIB2 IgG
 
1
 
’s were isolated using Affi-Gel Protein A
Maps II system (Bio-Rad Labs, Hercules, CA). After purification of rat
IgG
 
1
 
, the material was put through a 10DG desalting column, concen-
trated by centrifugation and dialyzed against 100 mM sodium acetate
buffer, pH 5.0. Fab fragments were generated after 20 h of papain diges-
tion (20 mU enzyme/5–10 
 
m
 
g IgG protein, in 100 mM sodium acetate, pH
5.0, 50 mM cysteine, 1 mM EDTA) and reactions were terminated by ad-
dition of iodoacetamide. The presence of Fab fragments was assayed by
Coomassie blue staining of acrylamide gels as well as by Western blotting
using secondary antibodies. Completion of the reaction was monitored by
the disappearance of high molecular weight intact antibody and the ap-
pearance of low molecular weight proteins comigrating with commercial
Fab’s. Western blotting with anti-[Fab]
 
2
 
 antibodies verified the absence of
the latter fragments in the digest. Intact AIIB2 antibody was efficiently
competed out by the Fab preparation, as shown by solution competition
and sequential immunostaining of S-1 acini. Once the presence and activ-
ity of the Fab’s was established, samples were treated with sodium azide
and dialyzed into DMEM:F12 before cell culture experiments.
 
Integrin Function-altering Assays
 
Antibodies and Fab’s and control non-immune mouse and rat IgG’s were
introduced into the cell-embedded substratum at the time of EHS gela-
tion. For the crude ascites of 
 
b
 
1- and 
 
b
 
4-integrins, we used a range of
25–200 
 
m
 
g ascites protein/ml; for purified 
 
b
 
1- and 
 
a
 
6-integrins and purified
mouse or rat IgG’s we used 2–25 
 
m
 
g/ml, 
 
z
 
10–150 nM. Cultures were
scored visually after 12 d. 10–20 random fields were viewed by phase con-
trast microscopy and the number of normal spheres or tumor-like colonies
were counted in each field and related to the behavior of control cultures
either without antibodies or in the presence of irrelevant antibodies. To
compare the reversion efficiency of various 
 
b
 
1-integrin antibodies and
Fab fragments on T4-2 cells, the diameter of 200 S-1 nonmalignant acini,
as observed directly by phase contrast microscopy, 
 
6
 
SEM was calculated
and the ratio of the tumor colony diameter to the nonmalignant S-1 acini
diameter 
 
6
 
SEM was determined.
 
Reversion Assay
 
Equal densities of cells were seeded into 3-D basement membranes and
were subjected to either 
 
b1-inhibitory integrin or mock-antibody (nonspe-
cific rat IgG) treatment. After 12 d, cells were photographed, released
from their matrices, and propagated as monolayers. They were then recul-
tured within the 3-D basement membrane assay with or without the
b1-integrin inhibitory antibody treatment. These steps were repeated two
more times.
Tumor Formation In Vivo
Tumor cells were propagated as monolayers, grown for 3–4 d in a 3-D-recon-
stituted basement membrane in the absence of antibody, released by dis-
pase (Collaborative Research), washed three times in DMEM:F12, and in-
cubated with 100 mg/ml function blocking b1-integrin antibody (clone
AIIB2), mock antibody (nonspecific rat IgG’s), or no treatment (control
group) for 3 h. Cell colonies were then washed three times in PBS and 1–4 3
106 cells were subcutaneously injected into the rear flanks of 4–6-wk-old
BalbC nu/nu mice, without further antibody treatment. Nontreated, non-
malignant S-1 cells were also injected into nude mice as negative controls.
Statistics were done by “unistat V 4.0 for windows.”
Experimental Subjects
In conducting research using animals, the investigators adhered to the
“Guide for the Care and Use of Laboratory Animals,” prepared by the
Committee on Care and Use of Laboratory Animals of the Institute of
Laboratory Animal Resources, National Research Council (NIH publica-
tion no. 86-23, revised 1985). In the conduct of research where human
specimens were used, the investigators adhered to the policies regarding
the protection of human subjects as prescribed by 32 CFR 219 and sub-
parts B, C, and D.
Results
S-1 and T4-2 Cells in a 3-D Basement Membrane 
Culture Assay Recapitulate the Phenotypic 
Characteristics of Normal and Malignant Breast
Tissue In Vivo
Only small differences in morphology and growth rates
could be observed between S-1 and T4-2 cells on tissue
culture plastic (not shown), but profound differences be-
came evident after only 4 d following their culture within a
3-D reconstituted basement membrane. Within 10 d, S-1
cells underwent morphogenesis and formed organized acini
reminiscent of those formed by cells from reduction mam-
moplasty, while T4-2 cells formed large, loosely disorga-
nized invasive colonies of cells similar to primary tumor cells
tested in this assay previously (Fig. 1, a and a9; Petersen et al.,
1992). In addition, S-1 cells were able to basally deposit
and organize a basement membrane, as shown by immu-
nostaining of type IV collagen (Fig. 1 b, and laminin, not
shown), thereby demonstrating that the cells were able to
form polarized structures. The irregular T4-2 colonies,
while staining for basement membrane components had
no discernible organized basement membrane (Fig. 1, b
and b9). The failure of T4-2 cells to undergo morphogene-
sis was also indicated by their compromised cell–cell adhe-
sion. This was shown by the absence of lateral E-cadherin
immunostaining (Fig. 1, c and c9), an increase in cytoplas-
mic localization of E-cadherin (cell fractionation and ex-
traction studies, not shown) and reduced interaction of
a- and b-catenins with E-cadherin (co-immunoprecipita-
tion, Fig. 1 d). Nevertheless, the two cell types expressed
essentially the same levels of the three cell adhesion pro-
teins (Fig. 1 e) indicating that the malignant conversion
was associated with compromised assembly of adherens
junctions rather than with down-regulation of these adhe-
sion proteins. Coincident with the formation of acini, S-1
cells became growth arrested and exited the cell cycle, as
demonstrated by negligible thymidine incorporation and
low immunostaining for Ki-67. Consistent with their loss
of structural organization, the tumorigenic T4-2 cells failed
to growth arrest by these criteria (Fig. 1, f and g).
S-1 and T4-2 Cells Differ in the Localization and 
Expression of ECM Integrin Receptors
We have postulated previously that tumor cells have lost
their ability to respond correctly to ECM-induced signalsWeaver et al. Reversion of the Malignant Phenotype by Integrin Antibodies 235
(Petersen et al., 1992; Howlett et al., 1995). To determine
if the loss of structural organization and growth control ex-
hibited by the tumor cells was related to an alteration in
their integrins, we characterized the integrin receptors for
laminin in the two cell lines. While both S-1 and T4-2 cells
expressed integrins b1, b4, a3, and a6, their distribution
patterns were radically different in 3-D cultures (Fig. 2, a
and a9 through d and d9). S-1 acini had basally distributed
b1-, b4-, and a6-integrins and basolateral a3-integrin, con-
sistent with their polarized phenotype. In contrast, all of
these integrins were found to be randomly distributed and
disorganized in the T4-2 colonies. Western blot analysis of
the tumor colonies showed over-expression of both b1-
and b4-integrins relative to the levels observed in the S-1
acini (Fig. 3, a and b). Cell surface labeling and immuno-
precipitation experiments revealed that the surface levels
of b1-integrins were slightly higher (12.5%) in the T4-2
cells (Fig. 3 c) whereas the surface b4-integrin levels were
much lower (60%) in T4-2 than in S-1 colonies (Fig. 3 d).
However, the ratio of b1- to b4-integrins at the cell surface
was increased by more than 2.8-fold in the T4-2 cell colo-
nies than in the S-1 acini (Fig. 3 e).
Figure 1. Characterization of the HMT-3522 human breast cancer model. (a and a9) Phase contrast micrographs of nonmalignant S-1
cell colonies (a) and tumorigenic T4-2 cell colonies (a9) viewed directly inside EHS for morphology: S-1 cells formed spherical structures
reminiscent of true acini (a), whereas T4-2 cells formed large irregular colonies (a9). (b and b9) Immunostaining for basement membrane
components: S-1 acini (b) stained for basement membrane proteins at the cell-ECM junctions as expected, while basement membrane
deposition in tumor colonies (b9) was clearly disorganized and no longer polarized. Comparable results were obtained for laminin (not
shown). (c and c9) Confocal fluorescence microscopy of cryosectioned colonies immunostained for E-cadherin: S-1 acini (c) stained for
E-cadherin primarily at the cell–cell junctions as is typically observed in normal breast sections. The T4-2 colonies (c9) showed punctate,
dispersed membrane and intracellular staining. (d) The b-catenin–E-cadherin interaction ratio as a measure of adherens junction assem-
bly: There was a 50% decrease in b-catenin protein coprecipitating with E-cadherin in T4-2 cells as compared to S-1 acini. Data are ex-
pressed as a ratio of b-catenin to E-cadherin densitometric measurements from duplicates of two separate experiments. Similar results
were observed for a-catenin (not shown). (e) Immunoblots of total levels of E-cadherin, a-catenin, and b-catenin: There were compara-
ble levels of all three adherens proteins in S-1 acini and T4-2 colonies. (f and g) Percent of thymidine and Ki-67 labeling in S-1 acini and
T4-2 colonies, expressed as thymidine and Ki-67 labeling indices from 3–4 separate experiments: Greater than 90% of the S-1 acini were
growth arrested (f), and had exited the cell cycle (g) whereas T4-2 colonies were still actively growing (f) and continued to cycle (g). All
cultures were analyzed after 10–12 d inside EHS. Bars: (a and a9) 16 mm; (b and b9) 25 mm; (c and c9) 8 mm.The Journal of Cell Biology, Volume 137, 1997 236
Figure 2. Immunofluorescence character-
ization of integrins in the HMT-3522 cells
in 3-dimensional cultures. (a–d) Cryosec-
tions of S-1 acini and (a9–d9) T4-2 colo-
nies, immunostained and examined by
confocal fluorescence microscopy for lo-
calization of b1- (a and a9), b4- (b and b9),
a6- (c and c9), and a3-integrin (d and d9)
localization:  b1-,  b4-, and a6-integrins
were targeted to the cell-ECM junction in
the S-1 acini (a–c), in contrast, in T4-2 col-
onies (a9–c9) this polarized-basal distribu-
tion was lost. S-1 acini exhibited basolat-
eral a-3 integrins (d), whereas T4-2 colonies
(d) demonstrated disorganized plasma
membrane and cytosolic expression of this
integrin. All cultures were analyzed after
10–12 d inside EHS. Bars: (a–d and a9–d9)
16 mm.Weaver et al. Reversion of the Malignant Phenotype by Integrin Antibodies 237
Function Blocking b1-Integrin Antibodies Cause 
Dramatic Phenotypic Reversion of the T4-2 Cells
Since T4-2 cells had both a higher total level and an ele-
vated ratio of cell surface b1- to b4-integrins, we won-
dered whether the aberrant malignant behavior may be a
reflection of the changes in these integrins. Accordingly,
we examined the consequences of treatment in 3-D with
varying concentrations of a previously characterized rat
monoclonal  b1-integrin antibody (clone AIIB2) which has
been shown to inhibit ligand binding (Werb et al., 1989).
This antibody caused massive apoptosis in S-1 cells, as
shown previously (Howlett et al., 1995), while T4-2 cells
were refractory (Fig. 4). Remarkably however, in addition
to resistance to apoptosis, almost all the antibody-treated
T4-2 tumor cells assumed a morphology which was indis-
tinguishable from that observed in S-1 cultures and was
discernible as early as 4 d after incubation. When exam-
ined by light microscopy after 12 d, these cultures ap-
peared as if they had truly reverted to a “nonmalignant”
phenotype. We therefore cryosectioned the colonies and
examined their morphology by immunofluorescence con-
focal microscopy. As markers of normal acinar formation,
we examined both cytoskeletal organization and superim-
position and distribution of cadherins and catenins. Sec-
tions of S-1 acini revealed uniform and polarized nuclei
(stained with propidium iodide; red), well-organized fila-
mentous actin (FITC phalloidin; green) (Fig. 5 a), and uni-
formly superimposed E-cadherin and b-catenin at the lat-
eral cell–cell junctions (Fig. 5 b). In contrast, untreated or
IgG-treated tumor cells had polymorphic nuclei and a
grossly disorganized actin cytoskeleton, visualized as ran-
dom, hatched bundles (Fig. 5 a9). Additionally, E-cadherin
and b-catenin were no longer colocalized (Fig. 5 b9). In
contrast, b1-treated T4-2 cells (referred to as T4-b1) re-
vealed striking rearrangements of cytoarchitecture as dem-
onstrated by their well-organized actin (Fig. 5 a99), and cy-
tokeratin 18 intermediate filament (not shown) networks.
Furthermore, organized adherens junctions became evi-
dent in T4-b1 acini (Fig. 5 b99) and were accompanied by
the re-establishment of E-cadherin–catenin complexes (not
shown). These changes were shown to occur in greater
than 95% of the tumor colonies treated with blocking anti-
body, as quantified by analyzing the numbers of disorga-
nized vs organized spheroids in relation to the S-1 and the
Figure 3. Biochemical characterization of integrins in the HMT-
3522 cells after culture in 3-dimensions. (a and b) Western analy-
sis of b1- and b4-integrins: Total cell lysates of S-1 and T4-2 colo-
nies showed elevated expression of b1- (a) and b4-integrins (b) in
the tumor cell colonies. (c and d) Cell surface expression of b1-
and b4-integrin heterodimers using biotinylation: Tumor colonies
had 12.5% higher plasma membrane levels of b1- (c) but 60%
lower levels of b4-integrin heterodimers (d) than S-1 acini. (e)
Relative scan units (RSU) showing relative colony surface levels
of b1- and b4-integrin heterodimers: There was a 2.8-fold relative
increase in the ratio of b1-integrins to b4-integrin on the colony
cell surface of T4-2 colonies as compared to the S-1 acini. All cells
were analyzed after 10–12 d inside EHS.
Figure 4. Apoptosis induction in HMT-3522 cells by inhibitory
b1-integrin function blocking antibodies. Apoptotic labeling indi-
ces calculated for S-1 and T4-2 cultures treated with inhibitory
b1-integrin antibodies for 4 d in 3-dimensional cultures: Greater
than 70% of S-1 cells were induced to undergo apoptosis within 4 d
of incubation with b1-integrin function blocking antibody (S-1
b1) while the level of basal apoptosis was less than 5% in the iso-
type controls (S-1 IgG). In contrast T4-2 cells similarly treated
(T4 b1) were refractory and had an apoptosis rate comparable to
basal levels (T4-2 IgG). Results are the mean and SE of 3–6 sepa-
rate experiments of duplicates.The Journal of Cell Biology, Volume 137, 1997 238
mock-treated T4-2 cells (Fig. 5 c). Viability and growth as-
says conducted on cells grown as monolayers ruled out
toxicity (not shown). Interestingly, while treatment with the
inhibitory b1-integrin antibody reduced cell adhesion and
retarded the rate of cell proliferation when T4-2 cells were
grown in two-dimension, culture in a three-dimensional
reconstituted basement membrane was required for com-
plete expression of the reverted phenotype (not shown). 
An examination of markers of proliferation and cell cycle
status in T4-b1 cells revealed that they were growth ar-
rested as indicated by both a decrease in thymidine incor-
poration and the size of the acini which was now com-
posed of only 6–8 cells, similar to that observed for S-1
cells (Fig. 5, d and e). This was in marked contrast to the
average of 18–22 cells observed for nontreated T4-2 tumor
colonies and the high mean number of T4-2 nuclei which
incorporated [3H]thymidine (Fig. 5, d and e). T4-b1 colo-
nies also had dramatically decreased cyclin D-1 levels (Fig.
5  f) again comparable to that seen in S-1 cultures and
markedly reduced Ki-67 levels (not shown), suggesting
Figure 5. b1-inhibitory antibody treatment of tumor cells leads to the formation of reverted acini. (a–a99) Confocal fluorescence micros-
copy images of F actin: Both the S-1 (a) and T4-b1 reverted acini (a99) showed basally localized nuclei (propidium iodide) and organized
filamentous F-actin (FITC), while T4-2 mock-treated colonies (T4-2 IgG) had disorganized, hatched bundles of actin and pleiomorphic
nuclei (a9). (b–b99) Confocal immunofluorescence microscopy images of E-cadherin (FITC) and b-catenin (Texas red): In S-1 (b) and
T4-b1 reverted acini (b99), E-cadherin and b-catenins were colocalized and superimposed at the cell–cell junctions. (c) Quantitative
analysis of tumor cell conversion efficiency by b1-integrin function blocking antibodies: Greater than 95% of S-1 and T4-b1 colonies
were scored as organized, while 97% of T4-2 IgG colonies were considered disorganized. Other reversion criteria, such as scoring for actin
and cadherin organization also yielded comparable results (not shown). (d) Cell number per colony in S-1 acini, T4-2 IgG colonies and T4-
b1 acini from 3–5 experiments: Both S-1 and T4-b1-revertant acini contained 6–8 cells, while T4-2 IgG tumor colonies contained 18–22 cells
when scored after 10–12 d (d). (e) Percent of thymidine-labeled cells in S-1, T4-2 IgG, and T4-b1 colonies: While a high percentage of T4-2
IgG colonies (greater than 30%) were still actively growing, the T4-2 b1 revertant acini had a greatly reduced growth rate similar to that
observed in the S-1 acini. (f) Immunoblot of cyclin D1 levels in S-1, T4-2, T4-2 IgG, and T4-b1 colonies: The level of D1 cyclin was
clearly decreased to the level of S-1 acini after b1 inhibitory antibody treatment. (g and g9) Collagen IV deposition as an indicator of
basement membrane organization: T4-b1 reverted acini (g9) deposited an organized collagen IV-containing BM at the cell-ECM junctions,
similar to that observed in S-1 acini (see Fig. 1 b). Note the contrast with T4-2 mock–treated tumor colonies (g). (Comparable results
were obtained for laminin, not shown.) All cultures were analyzed after 10–12 d inside EHS. Bars: (a–a99and b–b99) 16 mm; (g and g9) 25 mm.Weaver et al. Reversion of the Malignant Phenotype by Integrin Antibodies 239
that most reverted cells had exited the cell cycle and there-
fore had a reduced propensity to proliferate.
Cryosections of T4-b1 colonies incubated with antibodies
against either collagen IV (Fig. 5 g9) or laminin (not shown)
revealed deposition of a basally distributed, almost contin-
uous basement membrane, with characteristics similar to
that observed in the S-1 acini (Fig. 1 b). In contrast, punc-
tate and inversely polarized collagen IV (Fig. 5 g) and
laminin immunostaining (not shown) were observed in the
mock-treated tumor colonies. Thus, these tumor cells had
retained the ability to deposit a basement membrane and
to form polarized structures if the correct structural cues
could be received.
The Inhibitory b1-Integrin Activity Is Necessary for 
Phenotypic Reversion
The AIIB2 monoclonal antibody (mAb) recognizes a re-
gion connecting the two putative extracellular ligand bind-
ing sites of the b1-integrin receptor, thereby inducing a
conformational change consistent with inhibition of recep-
tor activity (Takada and Puzon, 1993). To distinguish be-
tween integrin binding per se or a requirement for inhibi-
tion of signaling, we examined whether the T4-2 cells would
phenotypically revert upon treatment with a nonfunc-
tional (neither activating nor inhibiting) anti–b1-integrin
mAb (clone DF5; Korhonen et al., 1991), an alternate in-
hibitory anti–b1-integrin mAb (clone JB1a or J10; Stupack
et al., 1991), and an activating anti–b1-integrin mAb (clone
TS2/16; Weitzman et al., 1995), whose epitope was mapped
to the same region as the AIIB2 antibody (Takada and Pu-
zon, 1993). Only the b1-integrin function blocking anti-
bodies were found to be capable of inducing phenotypic
reversion of the T4-2 cells (Table I), implying that overex-
pression or altered signaling through a b1-integrin–spe-
cific pathway is at least in part responsible for the malig-
nant phenotype of these tumor cells. To investigate the
possibility that the inhibitory antibodies may have facili-
tated reversion by inducing clustering of the integrin re-
ceptors by divalent mAb-mediated cross-bridging, we pu-
rified the rat IgG1 AIIB2 mAb and made AIIB2 Fab
fragments (Miyamoto et al., 1995a,b). Significantly, both
the purified AIIB2 mAb and its Fab fragments were capa-
ble of inducing the same phenotypic reversion of the T4-2
tumor cells (Table I), indicating that it was the b1-integrin
function at the cell surface that needed to be reduced for
reversion to occur, rather than augmentation of integrin
signaling by receptor clustering per se. 
The Reversion Is Phenotypic and Reversible
To distinguish between a reversible, microenvironmen-
tally induced change as opposed to selection of possible
nonmalignant contaminants or genetically altered mutants,
we undertook a series of “reversion rescue” studies. De-
spite two rounds of reversion, rescue, monolayer propaga-
tion, and reculturing in 3-D, these cells were able to re-
sume their original tumorigenic phenotypes when cultured
in the absence of antibody (Fig. 6).
Treatment with b1-Inhibitory Antibody Is Sufficient to 
Significantly Reduce Malignancy In Vivo
To find out whether phenotypic reversion of tumor cells
would be sufficient to reduce tumorigenicity in vivo, we in-
jected tumor cells treated in suspension with b1-integrin
blocking mAb, mock mAb, or no treatment for 3 h, as well
as S-1 cells into nude mice. Within two weeks small nod-
ules were observed in all injected sites including the S-1
controls (not shown). Whereas these nodules regressed
rapidly in the S-1 and T4-b1 groups, actively growing tu-
mors were observed in greater than 75–90% of the mock
mAb or vehicle-treated T4-2 mice. Upon sacrifice we ob-
served both a significantly reduced tumor number and tu-
mor size in the T4-b1 group (Table II). These data suggest
that “normalization” of the tumor cell phenotype in cul-
ture has a counterpart in vivo where the malignant poten-
tial is reduced or lost.
Table I. Comparison of Various b1-Integrin Antibody 
Treatments on Colony Size in 3-Dimensional Culture
Description
Mean colony
size
Relative size ratio
of T4-2/S-1 colonies*
mm
S-1 50 cells 24.5 6 0.7 N/A
Control T4-2 cells
(nonspecific rat IgG’s)‡
74.3 6 2.4 3.03 6 0.03
Inhibitory b1-antibody-treated
cells, clone AIIB2 crude ascites
24.1 6 1.0 0.98 6 0.10
Inhibitory b1-antibody-treated
cells, clone AIIB2 purified IgG1
28.2 6 1.1 1.15 6 0.04
Inhibitory b1-antibody-treated
cells, clone AIIB2 Fab fragments
24.5 6 1.4 1.04 6 0.04
Inhibitory b1-antibody-treated
cells, clone JB1a crude ascites
(alternate inhibitory mAb)
32.3 6 1.4 1.32 6 0.06
Activating b1-antibody-treated cells,
clone TS2/16 crude ascites
(stimulatory mAb)
61.7 6 3.3 2.52 6 0.13
*The diameter of 200 S-1 acini as observed directly by phase contrast microscopy,
were measured after 12 d in 3-D culture using an eyepiece equipped with a microme-
ter spindle. The same measurements were made on 100–400 T4-2 colonies in the pres-
ence of 100 mg antibody ascites protein or 25 mg purified IgG/ml EHS matrix of vari-
ous b1-integrin antibodies (listed above). The average measurements of each of these
groups 6 SEM were calculated and the ratio of T4-2/S-1 diameters 6 SEM were de-
termined.
‡Comparable results were also obtained with nonfunction altering antibodies a6- (clone-
J1B5) and b1-integrin (clone DF5), which are not shown.
Table II. Effect of b1-Inhibitory Antibody Induced Phenotype 
Reversion on Tumorigenicity In Vivo
Treatment description
Total number
of tumors
per group
Tumor size
Large
tumors*
Small
tumors‡
Mice with
no tumors
Control
nontreated
T4-2 cells 15/16 14/16 1/16 1/16
Non-immune
rat IgG-treated
T4-2 cells 14/16 11/16 3/16 2/16
b1-integrin
function blocking
antibody-treated T4-2 cells 7/16 5/16§ 2/16 9/16§
*tumors .5 ,300 mm3.
‡tumors ,5 mm3.
§P , 0.005 by X2 test.The Journal of Cell Biology, Volume 137, 1997 240
Figure 6. Phenotypic reversion as opposed to selection. Phase contrast micrographs of T4-2 cells grown in the presence of anti–b1-integrin
function blocking antibody (T4 b1), mock antibody (nonspecific IgG’s) (T4-2 IgG) or no antibodies (T4-2) viewed directly inside EHS:
Despite two rounds of treatment, these antibody reverted cells were able to resume their original tumorigenic phenotypes when cul-
tured in the absence of antibody. All cultures were analyzed after 10–12 d inside EHS. Bar, 50 mm.Weaver et al. Reversion of the Malignant Phenotype by Integrin Antibodies 241
Malignant Conversion Is Associated with Alterations in 
a6- and b4-Integrins
The ability of T4-b1 cells to re-form a basally organized
basement membrane (Fig. 5 g9) indicated the re-establish-
ment of acinar polarity. Polarity has been shown to be as-
sociated with a basal localization of a6/b4-integrin het-
erodimers in keratinocytes (DeLuca et al., 1994). T4-b1
reverted acini had polar, basally localized a6- and b4-inte-
grins (compare Fig. 7, a–7 a9), increased cell surface b4-inte-
grin heterodimers (Fig. 7 b), and higher p21cip,waf-1 levels
(Fig. 7 c). These findings showed that the b1-integrin sig-
naling pathway was not only interconnected with catenin-
E-cadherin adherens junction assembly, but was also con-
nected to the a6/b4-integrin signaling pathway.
We therefore examined whether an alteration of a6/b4
signaling in the nonmalignant cells might lead to abroga-
tion of growth control, disruption of morphogenesis and
loss of polarity. We used clone 3E1 (Hessle et al., 1984), a
b4-integrin mAb that was shown to influence the function
of colon adenoma and prostatic carcinoma cells (Jewell et al.,
1995), and a protocol similar to that described for the b1-inte-
Figure 7. Alteration of a6/b4-integrin signaling in S-1 cells leads to the formation of disorganized colonies. (a and a9) Confocal fluores-
cence microscopy of double immunostaining for a6- (Texas red) and b4-integrins (FITC): T4-b1 revertant acini (a9) showed basally po-
larized a6- and b4-integrins, while T4-2 mock–treated (T-4 IgG) colonies (a) demonstrated disorganized, nonpolarized expression. (b)
Cell surface expression of b4-integrin heterodimers using biotinylation: Tumor colonies had lower cell surface levels of b4-integrin het-
erodimers (60% lower) relative to the S-1 acini (see Fig. 3 d), which were restored in the T4-b1 reverted acini (40% higher) relative to
the T4-2 colonies. (c) Immunoblot of p21cip,waf-1 levels in T4-2 IgG and T4-b1 colonies: The level of p21 protein was clearly increased in
the T4-b1 reverted acini. (d and d9) Phase contrast micrographs of S-1 nonmalignant acini (d) and tumorigenic T4-2 colonies (d9) viewed
directly inside EHS: S-1 cells formed spherical structures (d), whereas T4-2 cells formed large, irregular colonies (d9). (e and e9) Phase con-
trast micrographs of S-1 nonmalignant cells treated with function altering b4-integrin antibodies (e) and tumorigenic T4-2 cells treated
with function blocking b1-integrin antibodies (e9) viewed directly inside EHS: S-1 cells treated with b4-integrin antibodies formed large,
irregular colonies (e), while T4-2 cells treated with b1-integrin function-blocking antibody (e9) formed spherical structures similar to S-1
acini (see Fig. 1 a). All cultures were analyzed after 10–12 d inside EHS. Bar, 16 mm.The Journal of Cell Biology, Volume 137, 1997 242
grin  inhibitory antibody studies. Treatment of S-1 cells
with this antibody led to the abrogation of normal mor-
phogenesis and loss of growth control. Thus, b4-integrin
mAb-treated S-1 cells formed disorganized, large struc-
tures similar to T4-2 colonies (Fig. 7 e vs 7 d9). Interestingly
the treatment had little or no effect on T4-2 colonies (not
shown). The heterodimer partner for b4 is the a6-integrin
(Sonnenberg et al., 1988a). Treatment of nonmalignant
cells with GoH3 (Sonnenberg et al., 1988b), an a6-integrin
function-blocking antibody, led to similar results (not
shown). These findings suggest that the a6/b4 pathway not
only influences morphogenesis but is also involved in
growth regulation in nonmalignant MEC’s. Furthermore,
these results support the notion that the tumorigenic con-
version of the HMT-3522 cells may be associated with an
alteration in the a6/b4 signaling pathway. If this were so,
then treatment of T4-b1 acini with b4 function-altering an-
tibodies (or simultaneous treatment with b1 and b4 func-
tion-altering antibodies) should not alter the T4-b1 re-
verted phenotype. This in fact was found to be the case
(not shown).
Discussion
The use of a 3-D BM assay and two related human MEC
lines, one phenotypically “normal” and the other malig-
nant, have allowed us to examine the fundamental role of
integrins and their intimate relationship to adherens junc-
tions in the regulation of growth and tissue morphogene-
sis. The results described in this paper demonstrate not
only that misregulation of integrins may play a causal role
in the expression of malignancy in human epithelial breast
cells, but also that manipulations from the cell surface (such
as modification of the transmembrane signaling receptors),
can restore tissue form and function and reduce tumorige-
nicity in vivo. Thus, analogous to the effects following ret-
inoid treatment of leukemias, cell surface ECM-receptor
manipulations may offer a plausible alternative therapeu-
tic modality for solid epithelial tumors.
Our results showed that the T4-2 tumorigenic cells have
increased  b1-integrin expression and cell surface levels
which are associated with loss of growth control and per-
turbed morphogenesis. Moreover, a reduction of b1- cell
surface integrin activity was found to be sufficient to re-
vert this tumor phenotype. These observations are consis-
tent with the reciprocal relationship shown to exist between
proliferation and differentiation and changes in levels of
b1-integrins in keratinocyte cells (Jones et al., 1995), and
the anchorage-free growth described for kidney cells over-
expressing a downstream integrin signaling protein (Frisch
et al., 1996). Overexpression and perturbed signaling through
b1-integrin heterodimers have previously been reported in
primary and metastatic cancers of the breast, colon, skin,
and prostate (Cress et al., 1995; Fujita et al., 1995; Leppa
et al., 1995; Mortarini et al., 1995; Shaw et al., 1996). En-
hanced b1-integrin expression was also shown to be asso-
ciated with increased tumor aggressiveness, invasiveness,
and metastatic potential, and was found to correlate with
decreased patient survival (Friedrichs et al., 1995). How-
ever, a direct effect of the altered integrin expression on
the tumor phenotype was not demonstrated in these stud-
ies, although our results may offer a plausible explanation
for this relationship. Furthermore, the reported inhibition
of invasion and metastasis of bladder and gastric carci-
noma cells, by inhibitory b1-integrin antibodies or Arg-
Gly-Asp peptides may be by a mechanism similar to that
described in this paper (Saiki et al., 1990; Fujita et al., 1992). 
Despite dramatic differences in morphology, both the
nonmalignant and tumorigenic HMT-3522 cell lines ex-
pressed comparable levels of cell–cell adhesion proteins,
but the ability to form cytoskeletal-associated adherens com-
plexes was found to be compromised in the T4-2 cells. This
is a condition which has been shown to characterize mam-
mary carcinoma in situ and has been described for several
aggressive metastatic breast cancers in vivo and cell lines
in culture (Takeichi, 1993; Birchmeirer and Behrens, 1994;
Sommers, 1996). By inhibiting tumor cell b1-integrins we
were able to rescue adherens junction assembly and revert
the tumor phenotype of the T4-2 cells. These results are in
agreement with the metastasis-suppressor/epithelial-pro-
moting role of enhanced cell–cell interactions previously
shown in metastatic MB-435S/1 breast cells (Frixen et al.,
1991) and in HeLa cells (Doyle et al., 1995) transfected
with cell adhesion molecules. These observations also em-
phasize the plasticity of cell–cell junction perturbations,
and establish a definite link between integrin signaling, ad-
herens junction assembly and the coordinated formation
of a differentiated tissue structure, as has been previously
implied by studies in keratinocytes and kidney cells (Hodi-
vala et al., 1994; Ojakian and Schwimmer, 1994; Schoenen-
berger et al., 1994; Braga et al., 1995). While our findings
suggest an integrated mechanism, the key intermediates
still need to be identified, although perturbed adherens
junction assembly can be restored by kinase inhibitors sug-
gesting down-stream signal transduction molecules are in-
volved (Kinch et al., 1995). The possibility that cytoskeletal
proteins such as fascin, a new b-catenin–binding protein
which competes against junction assembly, and is thought
to interact with the actin cytoskeleton to promote filament
bundling and enhance cell motility, may play a role is in-
triguing and is under investigation (Tao et al., 1996). Also,
whether a manipulation of the catenin-E-cadherin path-
way would reciprocally affect integrins, or whether direct
restoration of adherens assembly would be sufficient to
lead to phenotypic reversion and inhibition of tumor for-
mation in this system remain important questions.
Polarity is associated with a basal localization of a6/b4-
integrin heterodimers in keratinocytes (DeLuca 1994), which
has been shown to direct intermediate filament organiza-
tion (Spinardi et al., 1993; Guo et al., 1995), while its activ-
ity correlates with an increase in the level of p21cip,waf-1
(Clarke et al., 1995), a gene important in growth arrest
(Harper et al., 1993). Our data showing reorganized inter-
mediate filaments, increased levels of p21cip,waf-1 and polar-
ized a6- and b4-integrins in T4-b1 acini, are consistent with
these findings and emphasize the existence of coordinate
b1–b4-integrin pathway interactions. Since we showed
that  a6- and b4-integrin perturbing antibodies were able
to disrupt normal MEC cell morphogenesis, this also
strongly implicates a6/b4-integrins in establishing mam-
mary gland morphogenesis and tissue organization, as has
been previously reported for kidney cells (Sorokin et al.,
1990; Matter and Laurie, 1994) and in b4-integrin knockout
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has yet to be determined although a role for actin and in-
termediate filament-associated proteins, interacting with
the b4-integrin cytoplasmic tail, such as that described for
neural BPAG1 should be considered (Yang et al., 1996).
Finally, because we were unable to perturb the morpho-
genesis induced by b1-integrin inhibition in the T4-b1 re-
verted acini either by sequential or simultaneous incubation
with function-altering b4-integrin antibodies, this indicates
to us that a genetic defect in a facet of a6/b4-integrin signal-
ing pathway may indeed be responsible for the observed
loss of growth control and tissue organization observed in
the T4-2 cells. Further experiments will be required to
clarify the validity of this argument.
We used a well studied parameter of cell cycle progres-
sion, cyclin D1, and of quiescence, p21cip,waf-1, in addition
to standard DNA replication and Ki-67 assays, to deter-
mine how the reverted tumor cells compared to function-
ally normal acini. By all these criteria, T4-b1 revertant col-
onies behaved like growth-arrested S-1 acini. It was also
clear from these studies that the formation of a BM ac-
companied the cessation of growth, confirming our previ-
ous findings of an inverse relationship between the pres-
ence of a BM and proliferation (Petersen et al., 1992;
Howlett et al., 1994; Desprez et al., 1995). It is therefore
plausible that the repression of tumorigenicity in vivo, as
documented in these studies may have been directly re-
lated to the observed growth arrest in culture. Thus, it is
reasonable to postulate that it is the balance of signals
transduced by the b1- and b4-integrin receptors (or the
corresponding a-integrin subunits) that allows these breast
cells to sense their microenvironment appropriately and
drive tissue organization and function. Therefore, inte-
grins must function in concert with growth factor signaling
pathways to determine the decision to grow or to undergo
morphogenesis. Very recently, Sastry et al. (1996) overex-
pressed chimeric a5- and a6/b1-integrins in quail muscle
cells and concluded that it is the cytoplasmic domain of
these integrins which determines proliferation or growth
arrest. Clearly then both direct and indirect evidence in
the literature points to the fact that integrins, much like
other biological parameters, are cell and tissue context spe-
cific. While the detailed molecular mechanism of b1-inte-
grin signaling in breast cells remains to be elucidated, it is
safe to conclude that a change in the surface-associated
b1-integrin sets into motion global changes in growth and
higher order tissue organization. The model system de-
scribed here offers the opportunity to elucidate how b1- and
a6/b4-integrin heterodimers, catenin-cadherin adherens
junction proteins, and growth factor pathways communi-
cate within and between epithelial cells in the 3-D tissue. 
The demonstrated plasticity of T4-2 cells, their ability to
revert to a near normal phenotype and remain quiescent
for up to one month in culture, as well as their reduced tu-
morigenicity in vivo is reminiscent of the “reversion” of
mouse teratocarcinoma cells by a normal embryonic mi-
croenvironment. In these seminal experiments, embryonal
carcinoma cells which were fused with normal blastocysts
were able to give rise to phenotypically normal, genetically
mosaic mice (Mintz and Illmensee, 1975; for review see
Mintz and Fleischman, 1981). While the conclusion of these
studies was that the teratocarcinoma cells did not possess
cancer-associated genetic defects, we show in our system
that despite the presence of genetic defects they could be
restrained by the normal tissue structure. A similar domi-
nant, tumor suppressor role of the embryonic microenvi-
ronment was shown by our previous work in which active
pp60src constructs attached to a lacZ gene, packaged in a
replication-defective virus, when injected into stage 24
chick embryos appeared as apparently normal blue cells in
a well formed background of feathers and tissues (Stoker
et al., 1990). Significantly, once these cells were removed
from the embryos, trypsinized and placed in culture, they
became rapidly transformed (Boudreau et al., 1995a). These
findings may also provide a possible mechanistic explana-
tion for the poorly understood phenomenon of both spon-
taneous breast tumor reversion, tumor cell dormancy, and
the sporadic occurrence of an auxiliary nodal metastasis in
which a true ductal carcinoma in situ (DCIS), complete
with a central necrosis and a surrounding intact basement
membrane is recapitulated (Barsky et al., 1994).
In conclusion, our results show that changes in tissue
structure are critical for the expression of the malignant
phenotype and that ECM receptors are important modu-
lators of this effect. Furthermore, these data underscore
the concept that it is the relative distribution and propor-
tion of cell surface integrins (undoubtedly in cooperation
with other receptors at the cell surface) and their inte-
grated down-stream events which maintain the structural
homeostasis of breast and possibly other epithelial tissues.
Therefore, tumor cells need not have lost their ability to
respond to ECM-generated signals, but rather alterations
in the level of the integrated signals can lead to aberrant
behavior. Our results may also have a bearing on why
some tumor cells retain strong cell-ECM interactions: inte-
grin switching may promote enhanced survival in alternate
microenvironments encouraging metastasis.
Most fundamentally, these studies show that despite a
number of prominent mutations, amplifications, and dele-
tions, signaling events which are linked to the maintenance
of normal tissue architecture are sufficient to abrogate ma-
lignancy and to repress the tumor phenotype. It is thus fair
to state that cellular and tissue architecture act as the most
dominant tumor-suppressor of all, and that the phenotype
can—and does—override the genotype as long as the tis-
sue architecture is maintained. These results may explain
why breast cancer takes so long to develop even in individ-
uals with inherited susceptibility. Finally, these studies
should further aid in the development of therapeutic pep-
tides and antibodies for the treatment of breast and other
solid tissue malignancies.
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